

EXHIBIT B

From: Kennedy, Natalie
Sent: Monday, February 12, 2024 9:00 AM
To: Patel, Priyata; laurafairmeny@quinnemanuel.com; DBerl@wc.com; eoberwetter@wc.com; tfletcher@wc.com; atrask@wc.com; smahaffy@wc.com; kkayali@wc.com; apan@wc.com; rebeccacarter@wc.com; handerson@wc.com; jbeazley@wc.com; rkrawetz@wc.com; rgriffin@wc.com; aargall@wc.com; tgregory@wc.com; sruby@cdkrlaw.com; drpogue@cdkrlaw.com; rfranks@cdkrlaw.com; Weiswasser, Elizabeth; Desai, Anish; Zhang, Yi; Yu, Tom; Recce, Rocco; Leicht, Kathryn; Lin, Zhen; Crozier, Jennifer Brooks; Van Beck, Kellie; Pepe, Christopher; Sieger, Matthew; agoldsmith@kelloggghansen.com; jhartman@kelloggghansen.com; Eylea Biosimilars; Eylea
Cc: QE - Samsung Bioepis; Sandra K. Law; Chad Taylor; Mike Cottler; Mascherin, Terri L.; Fogel, Louis E.; Van Horn, Shaun M.; Robert Cerwinski; Andrew Robey; Carl Shaffer; Max Gottlieb; mhissam@hfdrlaw.com; Bryant J. Spann; M. David Griffith Jr.; DG-Aflibercept
Subject: RE: Regeneron Ex Parte Communications

Counsel,

With regard to the court-ordered omnibus opposition to the motions to dismiss, it is our understanding that the PI Defendants' position is that the draft protective order does not allow for the filing of the court-ordered omnibus response across all four cases containing confidential information of each of the PI Defendants. Likewise, it is our understanding that defendants reject the offered compromise of filing the omnibus response under seal and promptly serving outside counsel for each PI Defendant with a full, unredacted copy of Regeneron's papers, and such that outside counsel may facilitate access to their clients on whatever terms the PI Defendants deem appropriate.

Please confirm our understanding.

Regards,

Natalie

The logo for the law firm Weil, featuring the word "Weil" in white text on a green rectangular background.

Natalie C. Kennedy
Pronouns: She/her/hers

Weil, Gotshal & Manges LLP
767 Fifth Avenue
New York, NY 10153
Natalie.Kennedy@weil.com
+1 212 310 8227 Direct
+1 212 310 8007 Fax

From: Patel, Priyata <Priyata.Patel@weil.com>
Sent: Thursday, February 8, 2024 5:08 PM

smahaffy@wc.com; kkayali@wc.com; apan@wc.com; rebeccacarter@wc.com; handerson@wc.com; jbeazley@wc.com; rkrawetz@wc.com; rgriffin@wc.com; aargall@wc.com; tgregory@wc.com; sruby@cdkrlaw.com; drpogue@cdkrlaw.com; rfranks@cdkrlaw.com; Weiswasser, Elizabeth <Elizabeth.Weiswasser@weil.com>; Desai, Anish <anish.desai@weil.com>; Kennedy, Natalie <Natalie.Kennedy@weil.com>; Zhang, Yi <Yi.Zhang@weil.com>; Yu, Tom <Tom.Yu@weil.com>; Recce, Rocco <Rocco.Recce@weil.com>; Leicht, Kathryn <Kathryn.Leicht@weil.com>; Lin, Zhen <Zhen.Lin@weil.com>; Crozier, Jennifer Brooks <Jennifer.Crozier@weil.com>; Van Beck, Kellie <Kellie.VanBeck@weil.com>; Pepe, Christopher <Christopher.Pepe@weil.com>; Sieger, Matthew <Matthew.Sieger@weil.com>; agoldsmith@kelloggghansen.com; jhartman@kelloggghansen.com; Eylea Biosimilars <Eylea.Biosimilars@weil.com>; Eylea <Eylea@wc.com>

Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; Sandra K. Law <skl@schraderlaw.com>; Chad Taylor <clt@simmermanlaw.com>; Mike Cottler <mcottler@geminilaw.com>; Mascherin, Terri L. <TMascherin@jenner.com>; Fogel, Louis E. <LFogel@jenner.com>; Van Horn, Shaun M. <SVanHorn@jenner.com>; Robert Cerwinski <rcerwinski@geminilaw.com>; Andrew Robey <arobey@hfdrlaw.com>; Carl Shaffer <cshaffer@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; mhissam@hfdrlaw.com; Bryant J. Spann <B Spann@tcspllc.com>; M. David Griffith Jr. <DGriffith@tcspllc.com>; DG-Aflibercept <DG-Aflibercept@NETORG8512690.onmicrosoft.com>

Subject: RE: Regeneron Ex Parte Communications

Thanks, Laura. We understand that the PI Defendants will also be prepared to discuss the draft protective orders. Thanks.

From: Laura Fairney <laurafairney@quinnemanuel.com>

Sent: Thursday, February 8, 2024 4:55 PM

To: Patel, Priyata <Priyata.Patel@weil.com>; DBerl@wc.com; eoberwetter@wc.com; tfletcher@wc.com; atrask@wc.com; smahaffy@wc.com; kkayali@wc.com; apan@wc.com; rebeccacarter@wc.com; handerson@wc.com; jbeazley@wc.com; rkrawetz@wc.com; rgriffin@wc.com; aargall@wc.com; tgregory@wc.com; sruby@cdkrlaw.com; drpogue@cdkrlaw.com; rfranks@cdkrlaw.com; Weiswasser, Elizabeth <Elizabeth.Weiswasser@weil.com>; Desai, Anish <anish.desai@weil.com>; Kennedy, Natalie <Natalie.Kennedy@weil.com>; Zhang, Yi <Yi.Zhang@weil.com>; Yu, Tom <Tom.Yu@weil.com>; Recce, Rocco <Rocco.Recce@weil.com>; Leicht, Kathryn <Kathryn.Leicht@weil.com>; Lin, Zhen <Zhen.Lin@weil.com>; Crozier, Jennifer Brooks <Jennifer.Crozier@weil.com>; Van Beck, Kellie <Kellie.VanBeck@weil.com>; Pepe, Christopher <Christopher.Pepe@weil.com>; Sieger, Matthew <Matthew.Sieger@weil.com>; agoldsmith@kelloggghansen.com; jhartman@kelloggghansen.com; Eylea Biosimilars <Eylea.Biosimilars@weil.com>; Eylea <Eylea@wc.com>

Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; Sandra K. Law <skl@schraderlaw.com>; Chad Taylor <clt@simmermanlaw.com>; Mike Cottler <mcottler@geminilaw.com>; Mascherin, Terri L. <TMascherin@jenner.com>; Fogel, Louis E. <LFogel@jenner.com>; Van Horn, Shaun M. <SVanHorn@jenner.com>; Robert Cerwinski <rcerwinski@geminilaw.com>; Andrew Robey <arobey@hfdrlaw.com>; Carl Shaffer <cshaffer@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; mhissam@hfdrlaw.com; Bryant J. Spann <B Spann@tcspllc.com>; M. David Griffith Jr. <DGriffith@tcspllc.com>; DG-Aflibercept <DG-Aflibercept@NETORG8512690.onmicrosoft.com>

Subject: RE: Regeneron Ex Parte Communications

Priya,

We will make 9am ET tomorrow work. Here is a dial-in:

Join Zoom Meeting

<https://quinnemanuel.zoom.us/j/82993020722?pwd=uT9B5Y9C0U7fHgSq4ttRIFY2zBp1so.1>

Meeting ID: 829 9302 0722

Password: 373651

One tap mobile

+13017158592,,82993020722#,,,,*373651# US (Washington DC)

+13126266799,,82993020722#,,,,*373651# US (Chicago)

Regards,
Laura

From: Patel, Priyata <Priyata.Patel@weil.com>

Sent: Thursday, February 8, 2024 3:12 PM

To: Laura Fairneny <laurafairneny@quinnemanuel.com>; DBerl@wc.com; eoberwetter@wc.com; tfletcher@wc.com; atrask@wc.com; smahaffy@wc.com; kkayali@wc.com; apan@wc.com; rebeccacarter@wc.com; handerson@wc.com; jbeazley@wc.com; rkrawetz@wc.com; rgriffin@wc.com; aargall@wc.com; tgregory@wc.com; sruby@cdkrlaw.com; drpogue@cdkrlaw.com; rfranks@cdkrlaw.com; Weiswasser, Elizabeth <Elizabeth.Weiswasser@weil.com>; Desai, Anish <anish.desai@weil.com>; Kennedy, Natalie <Natalie.Kennedy@weil.com>; Zhang, Yi <Yi.Zhang@weil.com>; Yu, Tom <Tom.Yu@weil.com>; Recce, Rocco <Rocco.Recce@weil.com>; Leicht, Kathryn <Kathryn.Leicht@weil.com>; Lin, Zhen <Zhen.Lin@weil.com>; Crozier, Jennifer Brooks <Jennifer.Crozier@weil.com>; Van Beck, Kellie <Kellie.VanBeck@weil.com>; Pepe, Christopher <Christopher.Pepe@weil.com>; Sieger, Matthew <Matthew.Sieger@weil.com>; agoldsmith@kelloggghansen.com; jhartman@kelloggghansen.com; Eylea Biosimilars <Eylea.Biosimilars@weil.com>; Eylea <Eylea@wc.com>

Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; Sandra K. Law <skl@schraderlaw.com>; Chad Taylor <clt@simmermanlaw.com>; Mike Cottler <mcottler@geminilaw.com>; Mascherin, Terri L. <TMascherin@jenner.com>; Fogel, Louis E. <LFogel@jenner.com>; Van Horn, Shaun M. <SVanHorn@jenner.com>; Robert Cerwinski <rcerwinski@geminilaw.com>; Andrew Robey <arobey@hfdrlaw.com>; Carl Shaffer <cshaffer@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; mhissam@hfdrlaw.com; Bryant J. Spann <BSpann@tcspllc.com>; M. David Griffith Jr. <DGriffith@tcspllc.com>; DG-Aflibercept <DG-Aflibercept@NETORG8512690.onmicrosoft.com>

Subject: RE: Regeneron Ex Parte Communications

[EXTERNAL EMAIL from priyata.patel@weil.com]

Laura,

Regeneron is available Friday 2/9 at any time before 10am ET. Please let us know if that works for the PI Defendants or provide alternate times.

Thanks,
Priya

From: Laura Fairneny <laurafairneny@quinnemanuel.com>

Sent: Thursday, February 8, 2024 12:46 PM

To: Patel, Priyata <Priyata.Patel@weil.com>; DBerl@wc.com; eoberwetter@wc.com; tfletcher@wc.com; atrask@wc.com; smahaffy@wc.com; kkayali@wc.com; apan@wc.com; rebeccacarter@wc.com; handerson@wc.com; jbeazley@wc.com; rkrawetz@wc.com; rgriffin@wc.com; aargall@wc.com; tgregory@wc.com; sruby@cdkrlaw.com; drpogue@cdkrlaw.com; rfranks@cdkrlaw.com; Weiswasser, Elizabeth <Elizabeth.Weiswasser@weil.com>; Desai, Anish <anish.desai@weil.com>; Kennedy, Natalie <Natalie.Kennedy@weil.com>; Zhang, Yi <Yi.Zhang@weil.com>; Yu, Tom <Tom.Yu@weil.com>; Recce, Rocco <Rocco.Recce@weil.com>; Leicht, Kathryn <Kathryn.Leicht@weil.com>; Lin, Zhen <Zhen.Lin@weil.com>; Crozier, Jennifer Brooks <Jennifer.Crozier@weil.com>; Van Beck, Kellie <Kellie.VanBeck@weil.com>; Pepe, Christopher <Christopher.Pepe@weil.com>; Sieger, Matthew <Matthew.Sieger@weil.com>; agoldsmith@kelloggghansen.com; jhartman@kelloggghansen.com; Eylea Biosimilars <Eylea.Biosimilars@weil.com>; Eylea <Eylea@wc.com>

Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; Sandra K. Law <skl@schraderlaw.com>; Chad

Taylor <clt@simmermanlaw.com>; Mike Cottler <mcottler@geminilaw.com>; Mascherin, Terri L. <TMascherin@jenner.com>; Fogel, Louis E. <LFogel@jenner.com>; Van Horn, Shaun M. <SVanHorn@jenner.com>; Robert Cerwinski <rcerwinski@geminilaw.com>; Andrew Robey <arobey@hfdrlaw.com>; Carl Shaffer <cshaffer@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; mhissam@hfdrlaw.com; Bryant J. Spann <BSpann@tcspllc.com>; M. David Griffith Jr. <DGriffith@tcspllc.com>; DG-Aflibercept <DG-Aflibercept@NETORG8512690.onmicrosoft.com>

Subject: RE: Regeneron Ex Parte Communications

Priya,

We disagree with many of the representations in your email and think it makes sense to meet and confer. The PI Defendants are available on Friday 2/9 at 10 am ET. Please let us know if that works for Regeneron.

Regards,

Laura

From: Patel, Priyata <Priyata.Patel@weil.com>

Sent: Wednesday, February 7, 2024 9:41 AM

To: Laura Fairney <laurafairney@quinnemanuel.com>; DBerl@wc.com; eoberwetter@wc.com; tfletcher@wc.com; atrask@wc.com; smahaffy@wc.com; kkayali@wc.com; apan@wc.com; rebeccacarter@wc.com; handerson@wc.com; jbeazley@wc.com; rkrawetz@wc.com; rgriffin@wc.com; aargall@wc.com; tgregory@wc.com; sruby@cdkrlaw.com; drpogue@cdkrlaw.com; rfranks@cdkrlaw.com; Weiswasser, Elizabeth <Elizabeth.Weiswasser@weil.com>; Desai, Anish <anish.desai@weil.com>; Kennedy, Natalie <Natalie.Kennedy@weil.com>; Zhang, Yi <Yi.Zhang@weil.com>; Yu, Tom <Tom.Yu@weil.com>; Recce, Rocco <Rocco.Recce@weil.com>; Leicht, Kathryn <Kathryn.Leicht@weil.com>; Lin, Zhen <Zhen.Lin@weil.com>; Crozier, Jennifer Brooks <Jennifer.Crozier@weil.com>; Van Beck, Kellie <Kellie.VanBeck@weil.com>; Pepe, Christopher <Christopher.Pepe@weil.com>; Sieger, Matthew <Matthew.Sieger@weil.com>; agoldsmith@kellogghansen.com; jhartman@kellogghansen.com; Eylea Biosimilars <Eylea.Biosimilars@weil.com>; Eylea <Eylea@wc.com>

Cc: QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; Sandra K. Law <skl@schraderlaw.com>; Chad Taylor <clt@simmermanlaw.com>; Mike Cottler <mcottler@geminilaw.com>; Mascherin, Terri L. <TMascherin@jenner.com>; Fogel, Louis E. <LFogel@jenner.com>; Van Horn, Shaun M. <SVanHorn@jenner.com>; Robert Cerwinski <rcerwinski@geminilaw.com>; Andrew Robey <arobey@hfdrlaw.com>; Carl Shaffer <cshaffer@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; mhissam@hfdrlaw.com; Bryant J. Spann <BSpann@tcspllc.com>; M. David Griffith Jr. <DGriffith@tcspllc.com>; DG-Aflibercept <DG-Aflibercept@NETORG8512690.onmicrosoft.com>

Subject: RE: Regeneron Ex Parte Communications

[EXTERNAL EMAIL from priyata.patel@weil.com]

Counsel,

First, Regeneron did not contact the Court on an *ex parte* basis to request a 40-page consolidated opposition brief to the PI Defendants' motions. Rather, consistent with arguments that Regeneron raised in advance of the January 5, 2024 hearing, the Court *ordered* that Regeneron file a single "omnibus response to the motions to dismiss[.]" See Order Setting Briefing Schedule dated Jan. 9, 2024 [Civ. A. No. 1:23-cv-94, ECF No. 69]. The PI Defendants had every opportunity to argue otherwise both before and during the hearing and failed to do so. After the Court ordered an omnibus response, Regeneron contacted the clerk's office solely to obtain clarity

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.